. 2024 Sep 20;79(11):2990–2998. doi: 10.1093/jac/dkae319

Table 3.

Final population pharmacokinetic model parameters for darunavir

Parameter (units)	Typical values (95% confidence-interval^a)
Clearance: CL (L/h)^b	8.05 (6.85–8.81)
Central volume of distribution: V (L)^b	46.3 (37.2–56.0)
Intercompartmental clearance: Q (L/h)^b	7.79 (6.34–9.05)
Peripheral volume of distribution: V2 (L)^b	82.6 (65.1–101.5)
Bioavailability: F	1 FIXED
Mean absorption transit time: MTT (h)	0.763 (0.655–0.910)
Number of absorption transit compartments: NN (n)	11.6 (5.03–23.8)
First-order absorption rate constant: K_a (1/h)	0.551 (0.437–0.696)
Slope of AAG concentration effect on CL^c	−0.582 (−0.236 to −0.667)
BSV (%)
Clearance	32.4 (25.5–40.8)
BOV (%)
Bioavailability	44.4 (31.7–55.5)
Mean absorption transit time	60.8 (48.8–79.7)
First-order absorption rate constant	43.4 (31.8–58.5)
Residual unexplained error
Proportional error (%)	12.5 (10.6–15.0)
Additive error (mg/L)	0.291 (0.202–0.382)

BOV, between-occasion variability.

^aBased on sampling importance resampling.

^bAll clearances and volumes of distribution were allometrically scaled, and the typical values reported here refer to a child weighing 26 kg.

^cThe relationship between CL and AAG is as follows: $C L_{i} = 8.05 \cdot (W T_{i} / 26)^{0.75} \cdot {(e)}^{- 0.582 \cdot (A A G_{i} - 0.66)}$ , where Weight_i, CL_i and AAG_i are the values of weight, CL and AAG for patient i.